Bepo

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

By Medincell20/09/2020No Comments

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

20/09/2020

Previous PostExpert Review Report: Medical Safety of Ivermectin
Next PostEffects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle

Nos engagements

Signalement éthique

Mentions légales

Protection des données

Better medicine for all

Website by ScreenUp